SLC43A2 Antibodies

Large neutral amino acids transporter small subunit 4 (SLC43A2)

Sodium-, chloride-, and pH-independent high affinity transport of large neutral amino acids. .

Gene Information

Human
Gene Name:	SLC43A2
Uniprot:	Q8N370
Entrez:	124935

Family

Belongs to:
SLC43A transporter (TC 2.A.1.44) family

Alternative Names

FLJ23848; large neutral amino acids transporter small subunit 4; LAT4amino acid transporter; L-type amino acid transporter 4; MGC34680; Solute carrier family 43 member 2; solute carrier family 43, member 2

Molecular Weight

Mass (kDA):
62.747 kDA

Genomic Context

Human
Location:	17p13.3
Sequence:	17; NC_000017.11 (1569254..1630014, complement)

Tissue Specificity

Detected in several tissues with higher expression in placenta, kidney and peripheral blood leukocytes. In the kidney, is detected in epithelial cells of the distal tubule and collecting duct. In the intestine, is expressed mainly in crypt cells of the intestinal microvilli and epithelial cells in the base of the villus.

Subcellular Localizations

Membrane; Multi-pass membrane protein.

Diseases

• Hyperplastic Polyp
• Endometrial Polyp

Pathways

• Transport
• Localization

PTMs

• Glycoprotein

• Phosphoprotein

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SLC43A2

Boster Bio - The Man Behind High-Affinity Primary Antibodies

This article will give you a brief history of Steven Boster and his bio. We'll also explore the best uses of the SLC43A2 marker, high-affinity primary antibodies, and background. For more information, please read on! Boster Bio: The Man Behind High - Affinity Primary Antibodies

Primary antibodies with high-affinity

In order to improve the efficiency of antibody generation, researchers have developed recombinant Fabs equipped with affinity tags. These Fabs can simultaneously capture beads and perform multiple antibody generation projects. However, it is possible that the recombinant Fabs may not be as effective against all antigens and therefore might not be the best choice for some applications. Therefore, further studies are necessary to determine the most effective peptides for high-affinity recombinant antibodies.

InsA(1) and InsA(4) plates are used for affinity-maturation testing. A high-affinity antibody has a lower KD value than the same antibody produced by mouse monoclonal antibodies. The amount of ligand a given antibody can bind will determine its affinity. The higher the affinity of a given antibody, the lower its KD value is.

Mice lacking the IgD marker cause abnormally slow generation of high-affinity IgM. As a result, the mice suffer from prolonged autoimmune diabetes. IgD is needed to transition from autoreactive IgM response to secondary antigen–specific antibody responses. These mice are considered the best choice to determine whether immunotherapy might be possible, despite the fact they do not work for the treatment of autoimmune disorders.

Humanizing the 7G6 antibody was the first step to develop these primary antibodies. CDRs were grafted onto IgG1 human backbones in order to achieve this. The IGHV3 & IGKV1 are common in humans and are thought less clinically immunogenic. A cysteine residue was substituted by a serine in CDR2 (the heavy chain). E2814 was named the final humanized antitau antibody.

After affinity maturation was complete, the secondary antigen was removed and the blots rinsed with TBS–T four times or twice with Tween-20. The blots were then scanned and fluorescent images were obtained using the Odyssey LiCor Clx scanner and Image Studio software. The best Fab for ADAM17 peptide served as a reference in these experiments.

The immune system is dependent on the SLC43A2 proteins, so it is important to identify a specific antibody in order to improve patient outcomes. This marker will make it easy to develop high-affinity primaries antibodies. With this simple and effective method, it is possible to develop effective antibodies. You can work with the SLC43A2 mark and its variants immediately.

The IgD class BCR is a key regulator for antibody secretion in vivo. This receptor is essential for activation of B cells. It is required to perform CXCR4 function and affinity maturity. Hence, antibodies derived from IgD-deficient B cells could have a lower threshold for activation. This marker is critical for efficient antibody development and research.